Darunavir: promising initial results

Lancet

Volumn 369, Issue 9568, 2007, Pages 1143-1144

  MacArthur, Rodger D ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; VIREMIA; VIRUS VIRULENCE;

EID: 34047198578     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60499-1     Document Type: Note

References (12)

1. Gulick R., Mellors J., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337 (1997) 734-739
2. Mocroft A., Ledergerber B., Viard J., et al. Time to virologic failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 190 (2004) 1947-1956
3. Clotet B., Bellos N., Molina J., and on behalf of the POWER 1 and POWER 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and POWER 2: a pooled subgroup analysis from two randomised trials. Lancet 369 (2007) 1169-1178
4. Hicks C., Cahn P., Cooper D., et al., on behalf of the RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
5. Lalezari J., Henry K., O'Hearn M., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 (2003) 2175-2185
6. Lazzarin A., Clotet B., Cooper D., et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348 (2003) 2186-2195
7. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2. Denver, Colorado, USA: 13th Conference on Retroviruses and Opportunistic Infections, Feb 5-8, 2006: abstr 157.
8. Youle M., Staszweski S., Clotet B., et al. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials 7 (2006) 86-96
9. MacArthur R., Perez G., Walmsley S., et al. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials 6 (2005) 127-135
10. Loutfy M., Walmsley S., Mullin C., et al. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis 6 (2005) 284-290
11. Staes M., Van Craenenbroeck E., Vermeiren H., et al. Analysis of susceptibility and cross-resistance between TMC114 and other protease inhibitors among >56,000 routing samples, using linear regression model-based fold change predictions. Antivir Ther 11 (2006) S33
12. King M., Young T., Bernstein B., et al. Phenotypic susceptibility to TMC-114 and tipranavir before and after lopinavir/ritonavir-based treatment in subjects demonstrating evolution of lopinavir resistance. Antivir Ther 11 (2006) S34